



Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

SUPPLEMENTARY FIGURES


A



B



Supplementary Figure S1: Poor prognosis is associated with high Btk expression. **A.** Using TCGA glioma dataset (GBMLGG, N=660), we found that a significant higher Btk expression was found in glioma patients with high risk (red). **B.** A shorter patient survival was also found significantly correlated with Btk expression in the same dataset.



Supplementary Figure S2: Ectopic overexpression of Btk in U87MG cells led to increased c-Myc, Akt/mTOR signaling and vimentin expression.